Dr. James Labelle
Claim this profileUniversity of Chicago
Studies Aplastic Anemia
Studies Sickle Cell Disease
6 reported clinical trials
17 drugs studied
Affiliated Hospitals
Clinical Trials James Labelle is currently running
Extended vs Short-Term Abatacept Dosing
for Graft-versus-Host Disease
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.
Recruiting0 awards Phase 2
IST + BMT
for Aplastic Anemia
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia). This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms. This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
Recruiting2 awards Phase 3
More about James Labelle
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments James Labelle has experience with
- Fludarabine
- Alemtuzumab
- Cyclosporins
- Tacrolimus
- Mycophenolate Mofetil
- Tisagenlecleucel
Breakdown of trials James Labelle has run
Sickle Cell Disease
Klinefelter Syndrome and Triple X Syndrome.
Dyskeratosis Congenita
Dyskeratosis congenita
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does James Labelle specialize in?
James Labelle focuses on Aplastic Anemia and Sickle Cell Disease. In particular, much of their work with Aplastic Anemia has involved treating patients, or patients who are undergoing treatment.
Is James Labelle currently recruiting for clinical trials?
Yes, James Labelle is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that James Labelle has studied deeply?
Yes, James Labelle has studied treatments such as Fludarabine, Alemtuzumab, Cyclosporins.
What is the best way to schedule an appointment with James Labelle?
Apply for one of the trials that James Labelle is conducting.
What is the office address of James Labelle?
The office of James Labelle is located at: University of Chicago, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.